LC
CPRX

Lindbrook Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Lindbrook Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$6.3K Buy
260
+117
+82% +$2.63K ﹤0.01% 1861
2024
Q4 		$2.98K Buy
143
+3
+2% +$64 ﹤0.01% 2180
2024
Q3 		$2.78K Hold
140
– – ﹤0.01% 2242
2024
Q2 		$2.17K Buy
140
+109
+352% +$1.7K ﹤0.01% 2321
2024
Q1 		$494 Sell
31
-207
-87% -$3.12K ﹤0.01% 2519
2023
Q4 		$4K Buy
238
+150
+170% +$2.05K ﹤0.01% 2008
2023
Q3 		$1.03K Buy
88
+51
+138% +$682 ﹤0.01% 2351
2023
Q2 		$497 Sell
37
-23
-38% -$331 ﹤0.01% 2513
2023
Q1 		$995 Sell
60
-56
-48% -$924 ﹤0.01% 2451
2022
Q4 		$2.16K Sell
116
-340
-75% -$5.24K ﹤0.01% 2200
2022
Q3 		$6K Buy
456
+453
+15,100% +$5.37K ﹤0.01% 1548
2022
Q2 		$0 Hold
3
– – ﹤0.01% 2526
2022
Q1 		$0 Buy
+3
New +$21 ﹤0.01% 2491

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Lindbrook Capital's CPRX Position: Q1 2025 in Review

Lindbrook Capital increased its Catalyst Pharmaceutical (CPRX) stake by 82% in Q1 2025, buying an estimated $2.63K and bringing the position to 260 shares worth $6.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1861.

Lindbrook Capital first reported a position in CPRX in Q1 2022 and has held it in 13 quarters since. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Lindbrook Capital held 260 shares of Catalyst Pharmaceutical worth $6.3K as of Q1 2025.
  • Lindbrook Capital bought 117 Catalyst Pharmaceutical shares in Q1 2025, an estimated $2.63K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1861 holding.
  • Lindbrook Capital first reported a position in Catalyst Pharmaceutical in Q1 2022 and has held it in 13 quarters since.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.